Clinical outcomes


Last updated: 2021 Oct 30
Total hit(s): 67
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
No patient with a normal baseline value of platelets experienced a DLT or a grade 3 or above change in lymphocytes or platelets and those with grade 2 or 3 at baseline, did not experience a 2 or more grade increment in lymphocytes or platelets. Compared to the control group, there was an increased DLT rate and probability of toxicity in patients receiving 800 mg of the drug. A phase 2 trial with 800 mg molnupiravir can be conducted to study the effect of molnupiravir.
34450619
(J Antimicrob Chemother)
PMID
34450619
Date of Publishing: 2021 Aug 27
Title Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Author(s) nameKhoo SH, Fitzgerald R et al.
Journal J Antimicrob Chemother
Impact factor
4.94
Citation count: 8
Date of Entry 2021 Oct 30


Scores on the emotional exhaustion subscale of the Maslach Burnout Inventory significantly decreased at day 14, day 21, and day 28 in the patients treated with the drug. No difference in IL-1 plasma levels was found between the treatment and control groups at baseline and week 4. However, IL-1 levels significantly increased in both arms from baseline to week 4. During the study period no significant difference was seen in the plasma levels of CBD (15.23 ng/mL at day 7 and 20.62 ng/mL at day 21). A study with double-blind placebo-controlled design, longer follow-up period, multi-intervention dose, and multi-center design can be conducted to promote the use of Cannabidiol for reducing burnout symptoms in a population.
34387679
(JAMA Netw Open)
PMID
34387679
Date of Publishing: 2021 Aug 2
Title Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial
Author(s) nameCrippa JAS, Zuardi AW et al.
Journal JAMA Netw Open
Impact factor
5.032
Citation count: 2
Date of Entry 2021 Oct 30


Patients receiving active vitamin D medications [(17%) vs. (34%)], including calcimimetics [(8.2%) vs (32.6%)], paricalcitol or calcimimetics [(16.2%) vs (36.9%)], and also those on both paricalcitol and calcimimetics to treat secondary hyperparathyroidism (SHPTH) [(3.8%) vs (30.9%)] showed a lower mortality rate when compared to those who did not receive any drug. Only 19.9% of patients died in the Vitamin D medications group whereas 36.2% of patients died in the control group. A study with greater number of patients,proper information about all analytical variables and the absence of iselection bias and residual confounding can be conducted to draw conclusions.
34444716
(Nutrients)
PMID
34444716
Date of Publishing: 2021 Jul 26
Title Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
Author(s) nameArenas Jimenez MD, González-Parra E et al.
Journal Nutrients
Impact factor
4.21
Citation count: 2
Date of Entry 2021 Oct 30


Administration of chloroquine phosphate did not lead to significant differences in cardiac biomarkers or electrocardiograms. The median Troponin T levels were found to be 10.8 ng/L in the chloroquine group and 17.9 ng/L in the control group. Compared to the patients in the control group, the median NT-proBNP levels in the patients receiving chloroquine were higher ( 349ng/L vs 399 ng/L). No increased risk of ischemic heart injury or heart failure was observed in the patients receiving chloroquine. The use of chloroquine to treat COVID-19 cannot be recommended outside of clinical trials due to the lack of evidence of its efficacy and the increased risk it presents for arrythmia and sudden cardiac death.
34398893
(PLoS One)
PMID
34398893
Date of Publishing: 2021
Title No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not
Author(s) nameBeck-Friis J, Leach S et al.
Journal PLoS One
Impact factor
2.87
Citation count: 1
Date of Entry 2021 Oct 30


Amantadine administration resulted in the development of IgG antibodies in all the patients.The patients recovered successfully without the need to go to the hospital or be connected to a mechanical ventilator. Amantadine can be utilized as a cost-effective treatment option for SARS-CoV-2 when a vaccine is not available.
33040252
(Pharmacol Rep)
PMID
33040252
Date of Publishing: 2020 Dec
Title Observational study of people infected with SARS-Cov-2, treated with amantadine
Author(s) nameAranda-Abreu GE, Aranda-Martínez JD et al.
Journal Pharmacol Rep
Impact factor
5.1
Citation count: 13
Date of Entry 2021 Oct 30


The difference between CRP 1 and CRP 2 levels was significant (p=0.005) in the melatonin group (before and after receiving melatonin). The recovery percentage was higher in patients who received melatonin vs control group (85.7% VS 47.1%) .The percentage of symptom improvement was more in males than in females (62.5% VS 33.3%). Monitoring of cytokine,CRP levels and characterization of immune cells will provide a better picture about the impact of melatonin.
34418903
(Iran J Allergy Asthma Immunol)
PMID
34418903
Date of Publishing: 2021 Aug 7
Title A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement
Author(s) nameAlizadeh Z, Keyhanian N et al.
Journal Iran J Allergy Asthma Immunol
Impact factor
1.17
Citation count: 1
Date of Entry 2021 Sep 8


The remdesivir cohort had a significantly greater clinical recovery rate than the nonremdesivir cohort (65.2% vs 57.1%). Day 28 mortality in the remdesivir group was statistically lower than in the nonremdesivir cohort: 44 of 368 patients in the remdesivir cohort and 226 of 1399 patients in the nonremdesivir cohort had died.
The recovery rate was significantly higher in remdesivir treated patients on low-flow oxygen at baseline compared to that of the nonremdesivir cohort on low-flow oxygen ( 78.6% vs 65.7%, respectively). A lower mortality rate was seen in remdesivir treated cohort on low-flow oxygen at baseline compared with that of the nonremdesivir cohort on low-flow oxygen (4.3% vs 12..5%, respectively).
The use of corticosteroids along with remdesivir and non remdesivir control group should be studied.
34282406
(Open Forum Infect Dis.)
PMID
34282406
Title Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
Journal Open Forum Infect Dis.
Impact factor
N/A
Date of Entry 2021 Sep 27


Tocilizumab (TCZ) was used for the treatment of 46 critically ill COVID-19 patients and it do not show better survival compared to Dexamethasone. The need for ventilation cannot be avoided and gives no improvement from mortality. The need for mechanical ventilation is same between control and treatment group.
33893337
(Sci Rep)
PMID
33893337
Date of Publishing: 2021 Apr 23
Title Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
Author(s) nameRashad A, Mousa S et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 8
Date of Entry 2021 Aug 3


Dexamethasone was used for the treatment of 63 critically ill COVID-19 patients. It showed showed better survival of severe COVID patients compared to Tocilizumab. Dexamethasone gives better survival than Toclizumab and it cancels outs the need for ventilators.
33893337
(Sci Rep)
PMID
33893337
Date of Publishing: 2021 Apr 23
Title Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
Author(s) nameRashad A, Mousa S et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 8
Date of Entry 2021 Aug 3


No significant improvements were observed in clinical status (in terms of WHO 7-point ordinal scale) between different treatment groups (Lopinavir/Ritonavir, IFN--1a, Hydroxychloroquine) and control group patients on the 15th day and 29th day. The median age was 63 years,
the participants were mostly male (71.7%). The median time from symptom onset to randomization was 9 days.
The most frequent underlying conditions were obesity (28.7%), chronic cardiac disease (26.0%) and diabetes mellitus (22.0%). The remdesivir arm is continuing and currently enrolling patients. Thus, no clinical outcome for Remdesivir treatment is given.
Pre-print (medRXiv)
Title Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name -
Impact factor
N/A
Date of Entry 2021 Jun 14


Ivermectin-treated group patients had a lower mortality rate compared to the control group patients. Mortality also was lower in the subgroup of Ivermectin-treated patients with severe pulmonary involvement. Ivermectin treatment was shown to be associated with lower mortality rate. However, more clinical trials are underway.
33065103
(Chest)
PMID
33065103
Date of Publishing: 2021 Jan
Title Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study
Author(s) nameRajter JC, Sherman MS et al.
Journal Chest
Impact factor
7.22
Citation count: 81


No patients in the fluvoxamine-treated group had clinical deterioration, whereas 8.3% of patients in the placebo group showed clinical deterioration.
33180097
(JAMA)
PMID
33180097
Date of Publishing: 2020 Dec 8
Title Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) nameLenze EJ, Mattar C et al.
Journal JAMA
Impact factor
14.78
Citation count: 97


55.6% and 88.9% of patients showed positive outcomes when treated with Anakinra (ANK) and Tocilizumab (TCZ), respectively. Two patients who did not improve by TCZ drug treatment were treated successfully by ANK treatment. ANK is a potential alternative drug for treating patients who are not responding to TCZ.
32843231
(J Autoimmun)
PMID
32843231
Date of Publishing: 2020 Dec
Title High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) nameIglesias-Julián E, López-Veloso M et al.
Journal J Autoimmun
Impact factor
7.32
Citation count: 21


Patients treated with Anakinra within 36 hours after the onset of acute hypoxemic respiratory failure showed better improvement (without mechanical ventilation). Randomized controlled trials are needed to determine the safety and efficacy of anakinra in patients with COVID19
32602262
(Arthritis Rheumatol)
PMID
32602262
Date of Publishing: 2020 Dec
Title Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID19: A Case Series
Author(s) nameNavarro-Millán I, Sattui SE et al.
Journal Arthritis Rheumatol
Impact factor
7.34
Citation count: 49


Clinical outcomes in patients treated with IFX-1 (vilobelimab) showed a positive (but not significant) difference compared to the control group. The mortality by 28 days was 13% for the IFX-1 group and 27% for the control group. IFX-1 resulted in C5a inhibition and appeared to be safe and promising in treating severe COVID-19 patients. The Clinical results of the trial appeared to be effective and safe and thus recommended for the phase 3 trial.
33015643
(Lancet Rheumatol)
PMID
33015643
Date of Publishing: 2020 Dec
Title Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) nameVlaar APJ, de Bruin S et al.
Journal Lancet Rheumatol
Impact factor
N/A
Citation count: 56


Patients treated with the Remdesivir had better clinical improvement and less mortality than patients in the placebo group. The benefits of remdesivir was more when administered earlier in the illness. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/table/t3/)
32445440
(N Engl J Med)
PMID
32445440
Date of Publishing: 2020 Nov 5
Title Remdesivir for the Treatment of Covid-19 Final Report
Author(s) nameBeigel JH, Tomashek KM et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 2149


16 out of 17 COVID-19 patients with profound B-cell lymphopenia showed an effective improvement (in clinical symptoms and biological parameters) when treated with the passive transfer of COVID-19-neutralizing antibodies through CPT. Convalescent plasma with antiSARS-CoV-2 antibodies is a better approach for treating patients with prolonged COVID-19 symptoms who have impaired adaptive humoral response.
32959052
(Blood)
PMID
32959052
Date of Publishing: 2020 Nov 12
Title Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19
Author(s) nameHueso T, Pouderoux C et al.
Journal Blood
Impact factor
10.66
Citation count: 103


Compared to the HCQ alone or no treatment group patients, the combination-treated group patients (HCQ+ azithromycin) had a lower mortality rate. Age, mechanical ventilation/continuous positive airway pressure, and C reactive protein above the median were directly associated with death.
32926573
(Clin Transl Sci)
PMID
32926573
Date of Publishing: 2020 Nov
Title Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19
Author(s) nameLauriola M, Pani A et al.
Journal Clin Transl Sci
Impact factor
3.75
Citation count: 14


Compared to the control group patients (not-transfused), patients transfused within 72 hours of hospital admission had decreased mortality within 28 days. And a significant reduction in mortality was observed in patients transfused with high anti-RBD IgG titer COVID-19 convalescent plasma within 72 hours of admission.
32795424
(Am J Pathol)
PMID
32795424
Date of Publishing: 2020 Nov
Title Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Author(s) nameSalazar E, Christensen PA et al.
Journal Am J Pathol
Impact factor
3.71
Citation count: 95


A pregnant woman with severe COVID-19 was treated successfully with Tocilizumab and Remdesivir with better clinical improvement. Chest X-ray showed bilateral patchy infiltrates
32618794
(Obstet Gynecol)
PMID
32618794
Date of Publishing: 2020 Nov
Title Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Author(s) nameNaqvi M, Zakowski P et al.
Journal Obstet Gynecol
Impact factor
3.78
Citation count: 20


This case study involves a 68-year-old SARS-CoV-2 positive female patient with a medical history of coronary artery disease, was treated with Remedesivir. The patient experienced associated acute liver failure, which improved with the treatment of acetylcysteine. The patient had a medical history of hypertension, diabetes mellitus, hyperlipidemia, and coronary artery disease (CAD)
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 14


This case study is of an 80-year-old SARS-CoV-2 female patient who underwent acetylcysteine treatment to counteract Remdesivir associated acute liver failure. The patient had a medical history of hypertension, diabetes mellitus, and hyperlipidemia.
33006138
(Pharmacotherapy)
PMID
33006138
Date of Publishing: 2020 Nov
Title Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name Carothers C, Birrer K, Vo M.
Journal Pharmacotherapy
Impact factor
3.17
Citation count: 14


SARS-CoV-2 Patients associated with Severe Bronchospasm were treated with Ipratropium bromide, adrenaline, and magnesium sulfate. Patients showed remarkable improvement, were discharged from ICU to general floors
33173630
(Cureus)
PMID
33173630
Date of Publishing: 2020 Oct 6
Title Decreased Mortality in Patients With Severe Bronchospasm Associated With SARS-CoV-2: An Alternative to Invasive Mechanical Ventilation
Author(s) nameSalazar R Sr, Hallo A et al.
Journal Cureus
Impact factor
Cant find
Citation count: 1


This case study is of a 53-year-old immunocompromised female patient who had recurring symptoms despite Remdesivir therapy and had to undergo convalescent plasma therapy for persistent improvement in health. The patient tested negative for the first 21 days since the onset of symptoms. Hereafter the test came back positive. On day 54, SARS-CoV-2 PCR revealed viral RNA in the patients blood and stool. After the first Remdesivir therapy, no SARS-CoV-2-RNA was detectable in her blood and stool. But eight days after cessation of therapy, SARS-CoV-2 RNA was detected in blood and sputum. And finally, three weeks after the last convalescent plasma therapy, SARS-CoV-2 PCR from swabs and blood remained negative
33103195
(Clin Infect Dis)
PMID
33103195
Date of Publishing: 2020 Oct 26
Title Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Author(s) nameMalsy J, Veletzky L et al.
Journal Clin Infect Dis
Impact factor
7.71
Citation count: 17


Group of Patients treated with Arbidol recovered quickly from fever, stayed for a shorter duration in the hospital, and reported no side effects of the drug. 130 patients treated with arbidol were divided into two groups: Arbidol only (n=90) And Arbidol+other antiviral drugs (n=40). 90 patients not treated with arbidol were divided into two groups: Control (n=45) And Other antiviral drugs (n=45). Male patients were observed to have a higher risk of fever and tended to have more symptoms than females.
33097047
(Virol J)
PMID
33097047
Date of Publishing: 2020 Oct 23
Title Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series
Author(s) nameGao W, Chen S et al.
Journal Virol J
Impact factor
2.45
Citation count: 7